Stockreport

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF - Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA [Read more]